摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(4-氟苯基)硫烷基甲基]吡啶 | 83782-12-1

中文名称
2-[(4-氟苯基)硫烷基甲基]吡啶
中文别名
——
英文名称
2-(4-fluorophenylthiomethyl)pyridine
英文别名
2-(4-fluorophenylsulfanylmethyl)pyridine;2-{[(4-Fluorophenyl)sulfanyl]methyl}pyridine;2-[(4-fluorophenyl)sulfanylmethyl]pyridine
2-[(4-氟苯基)硫烷基甲基]吡啶化学式
CAS
83782-12-1
化学式
C12H10FNS
mdl
——
分子量
219.283
InChiKey
QBCKBUFMVRQDEY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    38.2
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:931f102b2dea52ae1527306dae6f9251
查看

反应信息

  • 作为反应物:
    描述:
    2-[(4-氟苯基)硫烷基甲基]吡啶Oxone 作用下, 以 二氯甲烷 为溶剂, 反应 48.0h, 生成 2-(4-fluorophenylsulfonylmethyl)pyridine
    参考文献:
    名称:
    WO2007/31747
    摘要:
    公开号:
  • 作为产物:
    描述:
    2-吡啶甲醇氯化亚砜potassium carbonate 作用下, 以 二氯甲烷乙腈 为溶剂, 反应 14.0h, 生成 2-[(4-氟苯基)硫烷基甲基]吡啶
    参考文献:
    名称:
    Regioselective Synthesis of 1-Sulfanyl- and 1-Selanylindolizines
    摘要:
    We describe herein a new approach to prepare unprecedented bioactive indolizine motifs decorated with organosulfur and organoselenium groups. A total of 12 1-sulfanylindolizines and 2 1-selanylindolizines were prepared in excellent yields by an intramolecular annulation of easily prepared chalcogen-containing pyridinium salts. The reaction is fast (1 h at 70 degrees C or 5 min under sonication) and transition-metal-free, using glycerol as a green solvent.
    DOI:
    10.1021/acs.joc.9b00871
点击查看最新优质反应信息

文献信息

  • 2-[(Phenylthio)methyl]pyridine derivatives: new antiinflammatory agents
    作者:Fortuna Haviv、Robert W. DeNet、Raymond J. Michaels、James D. Ratajczyk、George W. Carter、Patrick R. Young
    DOI:10.1021/jm00356a018
    日期:1983.2
    2-[(Phenylthio)methyl]pyridine derivatives inhibited the dermal reverse passive Arthus reaction (RPAR) in the rat. In the same model, indomethacin was inactive, and hydrocortisone was active. Compounds Ia-d also significantly reduced exudate volume and white blood cell accumulation in the pleural RPAR. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin
    2-[((苯硫基)甲基]吡啶衍生物可抑制大鼠皮肤逆向被动Arthus反应(RPAR)。在同一模型中,消炎痛是无活性的,氢化可的松是有活性的。化合物Ia-d还显着减少了胸膜RPAR中的渗出液量和白细胞积聚。这种活性模式与氢化可的松相似,与消炎痛不同。
  • Substitution of aqua ligands from cis-platinum(II) complexes bearing 2-(phenylthiomethyl)pyridine spectator ligands
    作者:Wakhiwe M. Mthiyane、Allen Mambanda、Deogratius Jaganyi
    DOI:10.1007/s11243-017-0182-4
    日期:2017.11
    second-order rate constant for the subsequent substitution of the aqua ligand trans to pyridine. The rate of substitution of the first aqua ligand decreases in the order: Pt(pySPh(t-But)) > Pt(pySPhF) > Pt(pySPh), while that of the second decreases in the order: Pt(pySPh(t-But)) > Pt(pySPh) > Pt(pySPhF), reflecting the influence of the substituents on the spectator ligands. 195Pt NMR spectra of aged solutions
    Cis-Pt(II)配合物,即[Pt2-(苯硫甲基)吡啶}(H2O)2](CF3SO3)2Pt(pySPh),[Pt2-(4-叔丁基苯硫甲基)吡啶}(H2O)2 ](CF3SO3)2Pt(pySPh(t-But)) 和 [Pt2-(4-fluorophenylthiomethyl)pyridine}(H2O)2](CF3SO3)2Pt(pySPhF) 被合成和表征。滴定法测定复合物的 pKa1 和 pKa2 值。使用停流和紫外-可见分光光度计技术,在伪一级条件下,在 pH 为 2 和离子强度为 0.1 M 的条件下,研究了硫脲亲核试剂取代这些配合物中的水配体。水配体的取代取决于传入配体的性质和浓度,具有低焓和激活值的负熵。第一个和第二个水配体的取代顺序发生并符合速率定律:kobs (1/2) = k(1/2) [Nu]。二级速率常数 k1 与反式取代为硫有关,而 k2 是随后将水配体
  • Indolizine Derivatives as Ligands of the Crth2 Receptor
    申请人:Hynd George
    公开号:US20080306109A1
    公开(公告)日:2008-12-11
    Compounds of formula (I) are CRTH2 antagonists, useful in the treatment of, for example, asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, and allergic rhinobronchitis. Formula (I) wherein R 1 , R 2 . R 3 and R 4 each independently are hydrogen, C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl, halo, —S(O) n R 10 , —SO 2 N(R 10 ) 2 , —N(R 10 ) 2 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 9 , —CO 2 R 10 , —C(O)R 9 , —NO 2 , —CN or —OR 11 ; wherein each R 9 is independently C 1 -C 6 alkyl, aryl, heteroaryl; R 10 is independently hydrogen, C 1 -C 6 alkyl, aryl, or heteroaryl; R 11 is hydrogen, C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl or a group —SO 2 R 10 ; n is 0, 1 or 2; R 5 is C 1 -C 6 alkyl, fully or partially fluorinated C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; R 6 is hydrogen, C 1 -C 6 alkyl or fully or partially fluorinated C 1 -C 6 alkyl; R 7 and R 8 are independently hydrogen or C 1 -C 6 alkyl, or R 7 and R 8 together with the atom to which they are attached form a cycloalkyl group; and X is —CHR 6 —, —S(O) n —, —C(O)—, —NR 6 SO 2 — or —SO 2 NR 6 - wherein n is 0, 1 or 2.
    式(I)的化合物是CRTH2拮抗剂,可用于治疗哮喘、慢性阻塞性肺疾病、鼻炎、过敏性气道综合征和过敏性鼻支气管炎等疾病。其中,R1、R2、R3和R4各自独立地为氢、C1-C6烷基、完全或部分氟化的C1-C6烷基、卤素、—S(O)nR10、—SO2N(R10)2、—N(R10)2、—C(O)N(R10)2、—NR10C(O)R9、—CO2R10、—C(O)R9、—NO2、—CN或—OR11;其中,每个R9独立地为C1-C6烷基、芳基、杂环芳基;R10独立地为氢、C1-C6烷基、芳基或杂环芳基;R11为氢、C1-C6烷基、完全或部分氟化的C1-C6烷基或一个基团—SO2R10;n为0、1或2;R5为C1-C6烷基、完全或部分氟化的C1-C6烷基、C1-C6烯基、C1-C6炔基、可选取代的芳基或可选取代的杂环芳基;R6为氢、C1-C6烷基或完全或部分氟化的C1-C6烷基;R7和R8独立地为氢或C1-C6烷基,或者R7和R8与它们连接的原子形成环烷基;X为—CHR6—、—S(O)n—、—C(O)—、—NR6SO2—或—SO2NR6-,其中n为0、1或2。
  • IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR
    申请人:Argenta Discovery Limited
    公开号:EP1931663A1
    公开(公告)日:2008-06-18
  • US4327102A
    申请人:——
    公开号:US4327102A
    公开(公告)日:1982-04-27
查看更多